Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.58 |
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12122944 | 1.00 | SLC17A5 (0.58) | SLC17A5MDM4TP53MDM2BRD4 | |
| SCHEMBL178559 | 1.00 | SLC17A5 (0.58) | SLC17A5MDM4TP53MDM2BRD4 | |
| SCHEMBL12119930 | 0.87 | SLC17A5 (0.44) | SLC17A5MDM4TP53MDM2BRD4 | |
| SCHEMBL29908094 | 0.79 | SLC17A5 (0.61) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL119188 | 0.79 | SLC17A5 (0.61) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL29401307 | 0.79 | SLC17A5 (0.61) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL27620508 | 0.79 | SLC17A5 (0.61) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL118371 | 0.77 | MDM4 (0.52) | SLC17A5MDM4TP53MDM2PTPN1 | |
| SCHEMBL19888241 | 0.76 | SLC17A5 (0.58) | SLC17A5MDM4TP53MDM2CASP3 | |
| SCHEMBL25354133 | 0.76 | MDM4 (0.52) | SLC17A5MDM4TP53MDM2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058945-A1 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058945-A1 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | FECH, HMOX1, FTH1 | SLC17A5 1725/4885MDM4 3970/4885TP53 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.